Jump to content

Masimo

From Wikipedia, the free encyclopedia
Masimo Corporation
Company typePublic
Industry
Founded1989; 36 years ago (1989)
FounderJoe Kiani
Headquarters
Irvine, California
,
U.S.
Area served
Worldwide
Key people
  • Michelle Brennan (chair)
  • Catherine Szyman (CEO)
RevenueIncrease US$2.09 billion (2024)
Decrease US$−267 million (2024)
Decrease US$−305 million (2024)
Total assetsDecrease US$2.63 billion (2024)
Total equityDecrease US$1.05 billion (2024)
Number of employees
c. 3,600 (2024)
Websitemasimo.com
Footnotes / references
[1]

Masimo Corporation is an American health technology and consumer electronics company headquartered in Irvine, California. The company develops patient monitoring devices, non-invasive sensors, and related software platforms used in hospital and home settings. Masimo has also operated in the consumer audio and wearable device markets.

History

[edit]

Masimo was founded in 1989 by engineer Joe Kiani; Mohamed Diab later joined as a co-developer.[2]

The company became publicly traded in 2007[3] and is listed on the Nasdaq under the ticker MASI. In 2011, Forbes included Masimo in a ranking of small public companies in the United States.[4][5]

In 2022, Masimo acquired Sound United, owner of audio brands including Bowers & Wilkins, Denon, Marantz, Definitive Technology, Polk Audio, Classé and Boston Acoustics. The company stated that the acquisition expanded its retail channels and engineering resources, and that it planned to use some audio products as connected hubs for its health-related services.[6]

See also: Apple Watch health monitoring patent dispute

In October 2023, the United States International Trade Commission (ITC) ruled that Apple Inc. had infringed patents held by Masimo related to light-based pulse oximetry in the Apple Watch product line. Masimo stated that Apple had recruited some of its engineers after discussions about a possible partnership, while Apple said it had evaluated multiple vendors and did not select Masimo.[7][8]

In September 2024, founder and CEO Joe Kiani resigned following a proxy contest involving an activist investor.[9][10]

On May 7, 2025, Masimo announced an agreement to sell its consumer audio division to Harman International, a subsidiary of Samsung Electronics, for US$350 million.[11]

Technology and products

[edit]

Signal Extraction Technology (SET) pulse oximetry

[edit]

Pulse oximetry estimates arterial oxygen saturation ([[SpO2]]) by comparing the absorption of red and infrared light. Motion and low perfusion can affect conventional pulse oximetry because venous blood movement may alter the signal.[12][13]

Masimo’s Signal Extraction Technology (SET) uses signal-processing algorithms to distinguish arterial from venous signals and to estimate SpO2, pulse rate, perfusion index (PI) and pleth variability index (PVI). Multiple clinical studies, mostly single-center or manufacturer-associated trials, have reported lower false-alarm rates and improved measurement stability compared with some earlier pulse oximetry systems, particularly in motion and low-perfusion conditions.[14][15]

SET-based devices have been studied in neonatology, perioperative care and intensive care. Individual studies have reported associations between use of these devices and outcomes such as changes in the incidence of retinopathy of prematurity in preterm infants, detection of critical congenital heart disease (CCHD) in newborns, ventilator weaning practices, and rapid-response activations in hospital wards.[16][17][18][19][20][21]

In 2011, the American Academy of Pediatrics and the U.S. Department of Health and Human Services recommended universal newborn screening for CCHD using motion-tolerant pulse oximeters validated in low-perfusion conditions.[22] In 2012, Masimo received FDA 510(k) clearance for devices and sensors labeled for use in screening newborns for CCHD in conjunction with a physical examination.[23]

In 2012, the National Health Service (NHS) Technology Adoption Centre in the United Kingdom included Masimo’s PVI among options for intraoperative fluid management technologies,[24] and in 2013 the French Society for Anaesthesia and Intensive Care (SFAR) noted PVI in its guidelines on perioperative hemodynamic optimization.[25]

Rainbow pulse co-oximetry

[edit]

Rainbow pulse co-oximetry uses multiple wavelengths of light to estimate several parameters noninvasively, including total hemoglobin (SpHb), carboxyhemoglobin (SpCO), and methemoglobin (SpMet), in addition to oxygen saturation (SpO2), pulse rate, perfusion index (PI) and pleth variability index (PVI).[26]

Several clinical studies have evaluated SpHb monitoring in perioperative and critical care settings, reporting reductions in the proportion of patients receiving transfusions and in transfusion volumes when SpHb was incorporated into transfusion protocols.[27][28][29] Studies in Emergency department settings have reported that SpCO monitoring may increase the detection of carbon monoxide poisoning and shorten time to diagnosis compared with some conventional approaches.[30][31][32]

The Pronto-7 device for noninvasive spot-checking of hemoglobin, SpO2 and pulse rate received a gold Medical Design Excellence Award,[33] and the World Health Organization listed noninvasive hemoglobin testing among technologies relevant to global health needs.[34]

Patient and consumer monitoring

[edit]

SafetyNet and Patient SafetyNet

[edit]

Patient SafetyNet is a remote monitoring and notification system used on medical–surgical care floors.[35] A study at Dartmouth-Hitchcock Medical Center reported a reduction in distress codes and intensive care transfers and estimated cost savings after implementing continuous monitoring with SET-based devices and Patient SafetyNet.[36][37]

A 2020 retrospective study at Dartmouth-Hitchcock examining sedative- and analgesic-associated inpatient respiratory arrest found that, during a ten-year period in which continuous monitoring with Masimo SET was used, no deaths or severe morbidity from opioid-induced respiratory depression were observed in monitored patients.[38] The ECRI Institute recognized Dartmouth’s use of the system with a Health Devices Achievement Award.[39]

During the COVID-19 pandemic, Masimo introduced Masimo SafetyNet, a telehealth system for remote patient monitoring that uses sensors connected to smartphones, with data transmitted to a HIPAA-compliant cloud platform.[40]

Rainbow acoustic monitoring

[edit]

Masimo’s acoustic respiration monitoring technology provides noninvasive, continuous measurement of respiration rate using an adhesive sensor with an integrated acoustic transducer placed on the patient’s neck.[41][42] Studies have reported that acoustic respiration rate monitoring has comparable accuracy and fewer false alarms than some respiration monitoring methods such as nasal capnography and impedance pneumography in selected patient groups.[43][44]

SedLine brain function monitoring

[edit]

SedLine is a brain function monitoring system that analyzes EEG activity from both hemispheres to derive an index of anesthetic depth.[45] Research has explored its use in tailoring anesthetic dosing and assessing emergence from anesthesia.

Capnography and gas monitoring

[edit]

Masimo offers mainstream and sidestream capnography and multigas analyzers for measurement of end-tidal carbon dioxide (CO2), nitrous oxide (N2O), oxygen (O2) and volatile anesthetic agents in operating rooms, procedural sedation environments and intensive care units.[46] A multi-center pediatric study reported that acoustic respiration rate had similar accuracy and precision to nasal capnography in certain settings.[47]

[edit]

In June 2020, Masimo released Bridge, a neuromodulation device intended to reduce symptoms of opioid withdrawal.[48]

In April 2023, the company received FDA De Novo clearance for a pulse-oximetry-based device designed to alert to respiratory depression as a potential early indicator of opioid overdose. The device was authorized for both prescription and over-the-counter distribution.[49]

Smartwatches and wearables

[edit]

In 2022, Masimo released the W1 smartwatch, which incorporates continuous physiological monitoring features and integrates with the company’s other monitoring platforms. The launch initially targeted a limited consumer release in the United States and telehealth providers internationally.[50]

References

[edit]
  1. ^ "Masimo Corp 2024 Annual Report (Form 10-K)". U.S. Securities and Exchange Commission. 2024-02-25.
  2. ^ "Masimo's Kiani: Stared Down Tyco". Orange County Business Journal. March 19, 2006.
  3. ^ "Joe Kiani, CEO, Chairman and Founder of Masimo Corporation, rings the NASDAQ opening bell". Nasdaq.com. 2008-08-07.
  4. ^ "The top 20 small public companies in America". Forbes.com. 2011-10-19.
  5. ^ "#19 Masimo". Forbes.com. 2011-10-19.
  6. ^ Newmarker, Chris (2022-12-14). "Masimo will turn millions of home entertainment systems into health hubs". MassDevice. Retrieved 2023-12-19.
  7. ^ Harding, Scharon (2023-10-27). "Apple Watch facing potential ban after losing Masimo patent case". Ars Technica. Retrieved 2023-12-18.
  8. ^ Song, Victoria (2023-12-18). "Apple to pull Apple Watch Series 9 and Ultra 2 this week due to ITC ban". The Verge. Retrieved 2023-12-18.
  9. ^ "Masimo Provides Leadership and Business Updates".
  10. ^ Gatlin, Allison (25 September 2024). "Masimo CEO Joe Kiani Resigns Following Politan Proxy Battle; Shares Jump". Investor's Business Daily.
  11. ^ Weatherbed, Jess (2025-05-07). "Samsung adds Bowers & Wilkins, Denon, Marantz, and Polk to its audio empire". The Verge. Retrieved 2025-05-07.
  12. ^ Mardirossian, G; Schneider, RE (1992). "Limitations of pulse oximetry". Anesth Prog. 39 (6): 194–6. PMC 2148612. PMID 8250340.
  13. ^ Barker, SJ; Tremper, KK (1987). "Pulse oximetry: Applications and limitations". Int Anesthesiol Clin. 25 (3): 155–75. doi:10.1097/00004311-198702530-00010. PMID 3323062. S2CID 42950128.
  14. ^ Malviya, S; Reynolds, PI; Voepel-Lewis, T; Siewert, M; Watson, D; Tait, AR; Tremper, K (2000). "False alarms and sensitivity of conventional pulse oximetry versus the SET technology in the pediatric postanesthesia care unit". Anesth Analg. 90 (6): 1336–40. doi:10.1097/00000539-200006000-00013. PMID 10825316. S2CID 24290526.
  15. ^ Barker, SJ (2002). ""Motion-resistant" pulse oximetry: a comparison of old and new models". Anesth Analg. 95 (4): 967–72. doi:10.1213/00000539-200210000-00033. PMID 12351278. S2CID 13103745.
  16. ^ Castillo, A; Deulofeut, R; Critz, A; Sola, A (2011). "Prevention of retinopathy of prematurity in preterm infants through changes in clinical practice and SpO2 technology". Acta Paediatrica. 100 (2): 188–92. doi:10.1111/j.1651-2227.2010.02001.x. PMC 3040295. PMID 20825604.
  17. ^ De-Wahl, GA; Wennergren, M; Sandberg, K; Mellander, M; Bejlum, C; Inganas, L; Eriksson, M; Segerdahl, N; Agren, A; Ekman-Joelsson, BM; Sunnegardh, J; Verdicchio, M; Ostman-Smith, I (2009). "Impact of pulse oximetry screening on the detection of duct dependent congenital heart disease: A Swedish prospective screening study in 39,821 newborns". Br Med J. 338 a3037. doi:10.1136/bmj.a3037. PMC 2627280. PMID 19131383.
  18. ^ Durbin, CG; Rostow, SK (2002). "More reliable oximetry reduces the frequency of arterial blood gas analysis and hastens oxygen weaning following cardiac surgery; a prospective randomize trial of the clinical impact of a new technology". Crit Care Med. 30 (8): 1735–40. doi:10.1097/00003246-200208000-00010. PMID 12163785. S2CID 10226994.
  19. ^ Taenzer, AH; Pyke, JB; McGrath, SP; Blike, GT (2010). "Impact of pulse oximetry surveillance on rescue events and intensive care unit (ICU) transfers: A before-and-after concurrence study". Anesthesiology. 112 (2): 282–87. doi:10.1097/ALN.0b013e3181ca7a9b. PMID 20098128.
  20. ^ Taenzer, AH; Blike, GT (2012). "Postoperative monitoring – the Dartmouth experience". APSF Spring-Summer Newsletter.
  21. ^ Forget, P; Lois, F; De Kock, M (2010). "Goal-directed fluid management based on the pulse oximeter–derived pleth variability index reduces lactate levels and improves fluid management". Anesth Analg. 111 (4): 910–4. doi:10.1213/ANE.0b013e3181eb624f. PMID 20705785. S2CID 40761008.
  22. ^ Ewer, AK; Furmston, AT; Middleton, LJ; Deeks, J; Daniels, JP; Pattison, HM; Powell, R; Roberts, TE; Parton, P; Auguste, P; Bhoyar, A; Thangaratinam, S; Tonks, AM; Satodia, P; Deshpande, S; Kumararatne, B; Sivakumar, S; Mupanemunda, R; Khan, KS (2012). "Pulse oximetry as a screening test for congenital heart defects in newborn infants: a test accuracy study with evaluation of acceptability and cost-effectiveness". Health Technol Assess. 16 (2): 1–184. doi:10.3310/hta16020. PMID 22284744.
  23. ^ "Masimo oximeters and neonatal sensors receive FDA 510(k) clearance with labeling for use in newborn screening for Critical Congenital Heart Disease (CCHD)" (Press release). PRNewswire.com. 2012-09-26.
  24. ^ "IOFM technology adoption pack published". Ntac.nhs.uk. Archived from the original on 2012-09-06. Retrieved 2012-08-05.
  25. ^ Vallet, B; Blanloeil, Y; Cholley, B; Orliaguet, G; Pierre, S; Tavernier, B (October 2013). "Guidelines for perioperative haemodynamic optimization" (PDF). Annales Françaises d'Anesthésie et de Réanimation. 32 (10): e151 – e158. doi:10.1016/j.annfar.2013.09.010. PMID 24126197. S2CID 43268634.
  26. ^ "Masimo Rainbow SET Pulse CO-Oximetry technology shown effective and efficient in detecting carbon monoxide poisoning in multiple clinical settings". Medicalnewstoday.com. Retrieved 2012-08-05.
  27. ^ "Anesthesiology News". Anesthesiology News. Retrieved 2012-08-05.
  28. ^ Awada, WNFM; Maher, F (2013). "Reduction in red blood cell transfusions during neurosurgery with noninvasive and continuous hemoglobin monitoring". p. 51.
  29. ^ Cros, Jérôme; Dalmay, François; Yonnet, Sandra; Charpentier, Matthieu; Tran-Van-Ho, Jessica; Renaudeau, François; Drouet, Anais; Guilbaut, Pierre; Marin, Benoit; Nathan, Nathalie (2019-08-03). "Continuous hemoglobin and plethysmography variability index monitoring can modify blood transfusion practice and is associated with lower mortality". Journal of Clinical Monitoring and Computing. 34 (4): 683–691. doi:10.1007/s10877-019-00367-z. ISSN 1573-2614. PMID 31376030. S2CID 199389128.
  30. ^ Suner, S; Partridge, R; Sucov, A; Valente, J; Chee, K; Hughes, A; Jay, G (2008). "Non-invasive pulse co-oximetry screening in the emergency department identifies occult carbon monoxide toxicity". J Emerg Med. 34 (4): 441–50. doi:10.1016/j.jemermed.2007.12.004. PMID 18226877.
  31. ^ Roth, D; Schreiber, W; Herkner, H; Havel, C (2014). "Prevalence of carbon monoxide poisoning in patients presenting to a large emergency department". Int J Clin Pract. 68 (10): 1239–45. doi:10.1111/ijcp.12432. PMID 24698635. S2CID 8935069.
  32. ^ Hampson, N (2012). "Noninvasive pulse co-oximetry expedites evaluation and management of patients with carbon monoxide poisoning". Am J Emerg Med. 30 (9): 2021–4. doi:10.1016/j.ajem.2012.03.026. PMID 22626815.
  33. ^ "Award winners | medical design excellence awards". Canontradeshows.com. 2005-10-22. Retrieved 2012-08-05.
  34. ^ "Noninvasive hemoglobin test (first ouchless & bloodless) makes world health organization's (WHO) list of innovative medical technologies that address global health concerns and needs…". www.healthcarereview.com. 2010-08-31. Archived from the original on 2011-01-01. Retrieved 2011-03-20.
  35. ^ Ostrovsky, G (2007-10-17). "Masimo Patient SafetyNet". Medgadget.com. Archived from the original on 2007-12-23. Retrieved 2008-01-04.
  36. ^ "Geisel School of Medicine - Closer watch, fewer Intensive Care Unit (ICU) trips, Dartmouth anesthesiologists find". Dms.dartmouth.edu. 2010-03-05.
  37. ^ "APSF Newsletter Spring-Summer 2012". Apsf.org. Retrieved 2012-08-05.
  38. ^ McGrath, Susan P.; McGovern, Krystal M.; Perreard, Irina M.; Huang, Viola; Moss, Linzi B.; Blike, George T. (2020-03-14). "Inpatient Respiratory Arrest Associated With Sedative and Analgesic Medications: Impact of Continuous Monitoring on Patient Mortality and Severe Morbidity". Journal of Patient Safety. 17 (8): 557–561. doi:10.1097/PTS.0000000000000696. ISSN 1549-8425. PMC 8612899. PMID 32175965.
  39. ^ "ECRI Institute announces winner of 4th annual health devices achievement award". Ecri.org. Archived from the original on 2012-12-20. Retrieved 2012-08-05.
  40. ^ Whooley, Sean (2022-07-05). "Masimo's SafetyNet monitoring reduced length of COVID-19 hospital stays, study says". MassDevice. Retrieved 2023-12-19.
  41. ^ "FDA clears Masimo Rainbow SET Acoustic Respiration Rate Monitor | News | RT: for decision makers in respiratory care". Rtmagazine.com. Archived from the original on 2012-03-21. Retrieved 2012-08-05.
  42. ^ Kumpula, JC; Rhonda, D; Harrison, RD (2010-10-18). "Accuracy of acoustic respiration rate monitoring in an acute nursing unit" (Abstract). ASA Abstracts. A1079.
  43. ^ Goudra, B; Penugonda, L (2011). "Monitoring respiration in upper GI endoscopy anesthesia" (ASA Presentation). A246.
  44. ^ Patino, M; Redford, DT; Quigley, TW; Mahmoud, M; Kurth, CD; Szmuk, P (Dec 2013). "Accuracy of acoustic respiration rate monitoring in pediatric patients". Paediatr Anaesth. 23 (12): 1166–73. doi:10.1111/pan.12254. PMID 24033591. S2CID 21984397.
  45. ^ Drover, DR; Lemmens, HJ; Pierce, ET; Plourde, G; Loyd, G; Ornstein, E; Prichep, LS; Chabot, RJ; Gugino, L (2002). "Patient state index: Titration of delivery and recovery from propofol, alfentanil, and nitrous oxide anesthesia". Anesthesiology. 97 (1): 82–9. doi:10.1097/00000542-200207000-00012. PMID 12131107. S2CID 3019914.
  46. ^ "Masimo enters noninvasive multigas monitoring, including capnography, with acquisition of PHASEIN". Medcitynews.com. 2012-08-01. Archived from the original on 2013-01-28. Retrieved 2012-08-05.
  47. ^ Patino, M; Redford, DT; Quigley, TW; Mahmoud, M; Kurth, CD; Szmuk, P (Dec 2013). "Accuracy of acoustic respiration rate monitoring in pediatric patients". Paediatr Anaesth. 23 (12): 1166–73. doi:10.1111/pan.12254. PMID 24033591. S2CID 21984397.
  48. ^ "Masimo announces device designed to reduce opioid withdrawal symptoms". MobiHealthNews. 2020-06-29. Retrieved 2022-05-19.
  49. ^ Hale, Conor (2023-04-03). "Masimo receives FDA clearance for first opioid overdose prevention monitor". Fierce Biotech. Questex LLC. Retrieved May 15, 2023.
  50. ^ "Masimo Launches Health Watch for Consumers on a Limited Basis". mddionline.com. 2022-05-02. Retrieved 2022-05-19.
[edit]
Retrieved from "https://en.wikipedia.org/w/index.php?title=Masimo&oldid=1325075902"